Logo image of SLRX

SALARIUS PHARMACEUTICALS INC (SLRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLRX - US79400X5032 - Common Stock

0.84 USD
+0.19 (+29.23%)
Last: 1/7/2026, 8:00:02 PM
0.835 USD
-0.01 (-0.6%)
After Hours: 1/7/2026, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SLRX. SLRX was compared to 529 industry peers in the Biotechnology industry. SLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SLRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SLRX has reported negative net income.
  • SLRX had a negative operating cash flow in the past year.
  • In the past 5 years SLRX always reported negative net income.
  • In the past 5 years SLRX always reported negative operating cash flow.
SLRX Yearly Net Income VS EBIT VS OCF VS FCFSLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • SLRX has a worse Return On Assets (-82.08%) than 68.75% of its industry peers.
  • SLRX has a Return On Equity (-117.81%) which is in line with its industry peers.
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
SLRX Yearly ROA, ROE, ROICSLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRX Yearly Profit, Operating, Gross MarginsSLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, SLRX has more shares outstanding
  • SLRX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SLRX is higher compared to a year ago.
SLRX Yearly Shares OutstandingSLRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K
SLRX Yearly Total Debt VS Total AssetsSLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -19.94, we must say that SLRX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -19.94, SLRX is doing worse than 82.39% of the companies in the same industry.
  • SLRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.94
ROIC/WACCN/A
WACCN/A
SLRX Yearly LT Debt VS Equity VS FCFSLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.28 indicates that SLRX has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.28, SLRX is not doing good in the industry: 61.17% of the companies in the same industry are doing better.
  • SLRX has a Quick Ratio of 3.28. This indicates that SLRX is financially healthy and has no problem in meeting its short term obligations.
  • SLRX has a Quick ratio of 3.28. This is comparable to the rest of the industry: SLRX outperforms 42.05% of its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
SLRX Yearly Current Assets VS Current LiabilitesSLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

  • SLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.10%, which is quite impressive.
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.17% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRX Yearly Revenue VS EstimatesSLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
SLRX Yearly EPS VS EstimatesSLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SLRX. In the last year negative earnings were reported.
  • Also next year SLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRX Price Earnings VS Forward Price EarningsSLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRX Per share dataSLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • SLRX's earnings are expected to decrease with -3.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for SLRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (1/7/2026, 8:00:02 PM)

After market: 0.835 -0.01 (-0.6%)

0.84

+0.19 (+29.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-19
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change4.16%
Market Cap4.92M
Revenue(TTM)N/A
Net Income(TTM)-5.00M
Analysts43.33
Price TargetN/A
Short Float %3.17%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-39.18
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z -19.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.38%
OCF growth 3YN/A
OCF growth 5YN/A

SALARIUS PHARMACEUTICALS INC / SLRX FAQ

Can you provide the ChartMill fundamental rating for SALARIUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SLRX.


What is the valuation status for SLRX stock?

ChartMill assigns a valuation rating of 0 / 10 to SALARIUS PHARMACEUTICALS INC (SLRX). This can be considered as Overvalued.


What is the profitability of SLRX stock?

SALARIUS PHARMACEUTICALS INC (SLRX) has a profitability rating of 0 / 10.


How sustainable is the dividend of SALARIUS PHARMACEUTICALS INC (SLRX) stock?

The dividend rating of SALARIUS PHARMACEUTICALS INC (SLRX) is 0 / 10 and the dividend payout ratio is 0%.